Clinical Trials Sponsored by Threshold Pharmaceuticals

Total 19692 results

Catabasis Pharmaceuticals

Completed

Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects

Healthy

United States
Catabasis Pharmaceuticals

Completed

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

Hypercholesterolemia

United States
ASLAN Pharmaceuticals

Terminated

Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC

Biliary Tract Cancer

Taiwan, Korea, Republic of, Singapore
CStone Pharmaceuticals

Completed

A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Solid Tumor, Adult

Australia
Arena Pharmaceuticals

Terminated

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

Inflammatory Bowel Diseases | Skin Extra-intestinal Manifestations

Belgium, Germany, Serbia
Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

Allergy

United Kingdom, New Zealand, Netherlands, Sweden
Prostrakan Pharmaceuticals

Completed

Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

Pain | Cancer

United States
Ferring Pharmaceuticals

Completed

A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment

Infertility

Japan
BioCryst Pharmaceuticals

Approved for marketing

Oral Berotralstat Expanded Access Program

Hereditary Angioedema | Prophylaxis | HAE
Boston Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris

Moderate to Severe Acne Vulgaris

United States, Canada
Catabasis Pharmaceuticals

Terminated

An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (GalaxyDMD)

Duchenne Muscular Dystrophy

United States, Canada, Australia, United Kingdom, Germany, Sweden
Boston Pharmaceuticals

Completed

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

Healthy Participants

United States
Boston Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis

Psoriasis

Australia
Boston Pharmaceuticals

Completed

Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects

Healthy Subjects

United Kingdom
Boston Pharmaceuticals

Completed

Study to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS172767 Enantiomers in Healthy Subjects

Healthy Participants

United Kingdom
Ferring Pharmaceuticals

Completed

A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment

Infertility

Belgium, Denmark, Spain, Czechia
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
Sunesis Pharmaceuticals

Terminated

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Lymphoplasmacytoid Lymphoma

United States
Endo Pharmaceuticals

Completed

Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women (RELEASE-2)

Edematous Fibrosclerotic Panniculopathy (Cellulite)

United States
Aerie Pharmaceuticals

Completed

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Ocular Hypertension | Glaucoma, Open-Angle

United States
MetiMedi Pharmaceuticals

Unknown

OMT-111 for Terminal Stage Solid Tumors

Breast Cancer | Pancreatic Cancer | Lung Cancer

Vietnam
Processa Pharmaceuticals

Terminated

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States
Jazz Pharmaceuticals

Completed

A Post-Marketing Observational Study of VYXEOS™

Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
CVI Pharmaceuticals

Unknown

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

Hyperlipidemia

China
Jazz Pharmaceuticals

Approved for marketing

A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA

Small Cell Lung Cancer
Ferring Pharmaceuticals

Completed

To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Alnylam Pharmaceuticals

Terminated

A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

Amyloidosis | Leukocyte Chemotactic Factor 2 Amyloidosis

United States, Malaysia, United Kingdom, Mexico, Egypt, India
Hope Pharmaceuticals

Terminated

A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients (CALISTA)

Calciphylaxis

United States, Canada, United Kingdom
Quark Pharmaceuticals

Completed

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant (ReGIFT)

Delayed Graft Function

United States, Spain, Canada, Australia, Netherlands, Germany, Belgium, France, Argentina, Brazil, Czechia
Braeburn Pharmaceuticals

Completed

Phase II Pharmacokinetics Study of CAM2038

Chronic Pain | Opioid Use Disorder

United States
Vanda Pharmaceuticals

Unknown

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Coronavirus Infection

United States
Veloxis Pharmaceuticals

Terminated

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

Autoimmune Hepatitis

United States, Canada
Veloxis Pharmaceuticals

Completed

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

Dyslipidemia

United States
Alexion Pharmaceuticals

Terminated

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment (EVIDENCE)

Atypical Hemolytic Uremic Syndrome

United States, Australia, Germany, United Kingdom
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

Healthy Volunteer

Belgium
Syndax Pharmaceuticals

Terminated

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma (ENGAGE-501)

Hodgkin's Lymphoma

United States
Ferring Pharmaceuticals

Completed

Cortiment® MMX Pharmacokinetic Study

Healthy

India
Bellicum Pharmaceuticals

Completed

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

Castrate Resistent Prostate Cancer

United States
Alexion Pharmaceuticals

Terminated

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Canada, United Kingdom
Aerie Pharmaceuticals

Completed

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Primary Open Angle Glaucoma or Ocular Hypertension

United States
Endo Pharmaceuticals

Completed

Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

Edematous Fibrosclerotic Panniculopathy

United States
Ferring Pharmaceuticals

Terminated

A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension

Portal Hypertension

Spain
Ferring Pharmaceuticals

Completed

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. (ProComD)

Advanced Prostate Cancer

Germany
Alexion Pharmaceuticals

Terminated

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

Hong Kong, United States, United Kingdom, Croatia, Malaysia, Korea, Republic of, Turkey, Japan, Italy, Spain, Taiwan, Australia, Argentina, Thailand, Russian Federation, Czechia, Denmark, Germany
Ferring Pharmaceuticals

Completed

A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON

Prostate Cancer

United Kingdom, Netherlands, Ireland, Greece, France, Belgium, Denmark, Norway, Italy, Slovakia, Switzerland, Portugal, Finland, Hungary, Germany
Jazz Pharmaceuticals

Completed

"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"

Obstructive Sleep Apnea | Narcolepsy

United States, France, Canada, Germany, Netherlands, Finland
Regeneron Pharmaceuticals

Completed

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

Healthy Volunteers

New Zealand
Concert Pharmaceuticals

Completed

Food Effect Study of CTP-543 in Healthy Volunteers

Healthy

United States
Aerie Pharmaceuticals

Completed

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Regeneron Pharmaceuticals

Completed

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)

Neovascular Age-Related Macular Degeneration

United States

3

Subscribe